birdrock, I get the cardio metabolic shtick but diversified needs an explanation.
The New Amarin is on the right track toward transforming into a global, diversified cardiometabolic player as we execute a thoughtful and practical strategic plan designed to create value now. About Amarin Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management.
I interpreted the "diversified cardiometabolic play" to be a statin Vascepa or a statin MND-2119 combo drug...It could be introduced in the U.S. as a patented drug.
Since statins and Vascepa have proven track records in reducing CVD, the combo drug should gain easy approval from the FDA.